MONITOR
Research type
Research Study
Full title
Monitoring Tuberculosis Treatment
IRAS ID
280133
Contact name
Mahdad Noursadeghi
Contact email
Sponsor organisation
Joint Research Office
Clinicaltrials.gov Identifier
Z6364106/2020/04/08 , Finance Data Protection
Duration of Study in the UK
4 years, 11 months, 30 days
Research summary
Novel approaches to monitor the responses to treatment of tuberculosis (TB) are needed to support infection control decisions, evaluate treatment efficacy and guide duration of antimicrobial therapy. This study aims to evaluate the application of a new sputum test. called the mycobacterial bacterial load (MBL) assay based on detection of the RNA of Mycobacterium tuberculosis (Mtb), and a new blood test for human blood RNA signatures of active TB, for monitoring the response to TB treatment.
The study involves obtaining sputum and blood samples with a diagnosis of TB, at the same time as other routine tests, before starting treatment and at selected time points after starting treatment in order to evaluate how well the new tests predict the response to treatment.
The results of this research study will help us in the future to confirm that we are giving the correct treatment, confirm when patient with TB is no longer infectious to other people, and confirm when they have been fully cured of the infection.
REC name
London - Stanmore Research Ethics Committee
REC reference
20/LO/1217
Date of REC Opinion
17 Nov 2020
REC opinion
Favourable Opinion